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Abstract
Metastatic castration-resistant prostate cancer (mCRPC) is a lethal
form of treatment-resistant prostate cancer and poses significant
therapeutic challenges. Deregulated receptor tyrosine kinase (RTK)
signalling mediated by loss of tumour suppressor Sprouty2 (SPRY2)
is associated with treatment resistance. Using pre-clinical human
and murine mCRPC models, we show that SPRY2 deficiency leads
to an androgen self-sufficient form of CRPC. Mechanistically,
HER2-IL6 signalling axis enhances the expression of androgen
biosynthetic enzyme HSD3B1 and increases SRB1-mediated choles-
terol uptake in SPRY2-deficient tumours. Systemically, IL6 elevated
the levels of circulating cholesterol by inducing host adipose lipo-
lysis and hepatic cholesterol biosynthesis. SPRY2-deficient CRPC is
dependent on cholesterol bioavailability and SRB1-mediated
tumoral cholesterol uptake for androgen biosynthesis. Importantly,
treatment with ITX5061, a clinically safe SRB1 antagonist,
decreased treatment resistance. Our results indicate that choles-
terol transport blockade may be effective against SPRY2-deficient
CRPC.
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Introduction
Prostate cancer is the most common malignancy in men. Treatment
resistance and cancer dissemination are the major causes of disease-
associated mortalities in most advanced cancers, including prostate
cancer. Androgens and androgen receptor (AR) are essential for
growth and survival of prostate cancer (Yap et al, 2016). Androgen
deprivation therapy (ADT) administered through surgical or medical
castration remains the current initial treatment for metastatic pros-
tate cancer. Despite an initial favourable response to ADT (even
when combined with upfront docetaxel chemotherapy), a majority
of the patients will progress to an advanced disease state termed
castration-resistant prostate cancer (CRPC). Although a subset of
the emerging CRPC may exhibit AR-independent characteristics, AR
reactivation remains as a significant feature of advanced disease
(Watson et al, 2015).
Experimental and clinical investigations have identified several
mechanisms that maintain AR activity through amplifications,
mutations and splicing of AR along with tumoral androgen biosyn-
thesis (Watson et al, 2015). The clinical success of abiraterone, an
androgen biosynthesis inhibitor, in improving the treatment
response highlights the importance of androgens in the emergence
of CRPC (James et al, 2017). Recent translational studies have also
revealed the causative role of HSD3B1, an androgen biosynthetic
enzyme, in the development of CRPC by intra-tumoral androgen
biosynthesis from cholesterol (Chang et al, 2013; Hearn et al,
2016). Studies implicating the association of tumoral cholesterol
biosynthesis and cholesterol uptake by lipoprotein receptors such
as low-density lipoprotein receptor (LDLR) and scavenger receptor
B1 (SRB1) in the development of CRPC have proposed a potential
role for cholesterol in prostate cancer progression (Kim et al, 2014;
Schorghofer et al, 2015; Furuya et al, 2016). Besides local tumour
factors, systemic physiological conditions such as dyslipidaemia
and chronic inflammation may also govern treatment response and
disease progression (Fearon et al, 2012). These factors are particu-
larly important in prostate cancer as both systemic cholesterol
homeostasis and pro-inflammatory cytokines such as IL6 have
been implicated in CRPC (Rice et al, 2012; Culig, 2014; Divella
et al, 2016). Therefore, studying the treatment response at a
systemic level may improve our current understanding of disease
progression.
1 Cancer Research UK Beatson Institute, Glasgow, UK
2 Institute of Cancer Sciences, Glasgow, UK
3 Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Headington, Oxford, UK
*Corresponding author. Tel: +44 141 330 8170; E-mail: r.patel@beatson.gla.ac.uk
**Corresponding author. Tel: +44 141 330 3658; E-mail: h.leung@beatson.gla.ac.uk
ª 2018 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine e8347 | 2018 1 of 19
Published online: March 14, 2018 
Comprehensive genomic and transcriptomic profiling revealed
activation of receptor tyrosine kinase (RTK)-mediated oncogenic
(RAS/ERK and PI3K/AKT) signalling pathways, coupled with inacti-
vation of tumour suppressors such as the lipid phosphatase PTEN
and the RAS/ERK pathway inhibitor Sprouty2 (SPRY2), in advanced
prostate cancer (Taylor et al, 2010). These oncogenic signalling
cascades can mediate treatment resistance in both AR-dependent
and independent manner (Mulholland et al, 2011; Rick et al, 2012).
Experimental models of prostate cancer have identified PTEN and
SPRY2 as important molecular determinants of aggressive prostate
carcinogenesis including metastases (Ahmad et al, 2011, 2013;
Schutzman & Martin, 2012; Patel et al, 2013; Assinder et al, 2015).
While PTEN loss has been implicated in driving both AR-dependent
and independent forms of CRPCs (Mulholland et al, 2011; Yang
et al, 2018), the functional contributions of SPRY2 deficiency in
promoting treatment resistance remain undefined.
Using murine pre-clinical models of prostate cancer, we show
how SPRY2 deficiency leads to treatment resistance. SPRY2 defi-
ciency causes CRPC by inducing enhanced cholesterol uptake
through the HER2-IL6 signalling axis and tumoral androgen biosyn-
thesis. By studying CRPC at an organism level, we have identified
systemic inflammation and cholesterol homeostasis as important
processes influencing the treatment response. Hence, building on
the extensive genomic profiles of clinical prostate cancer in the liter-
ature, we report on mechanistic insight into molecular determinants
that govern disease progression to CRPC.
Results
SPRY2 deficiency mediates CRPC
To evaluate the clinical significance of SPRY2 deficiency in govern-
ing treatment response, we investigated the prognosis of ADT-
treated prostate cancer patients based on the tumour levels of
SPRY2. Prostate cancer patients with low SPRY2 levels, defined as
below median histoscore, showed significantly lower relapse-free
and overall survival following ADT (Fig 1A and B). Similarly,
patients with low SPRY2 expression in TCGA prostate cancer
dataset also have significantly reduced relapse-free survival
(Fig EV1A; Cancer Genome Atlas Research, 2015). We next investi-
gated SPRY2 status in hormone-naı¨ve (HN) and CRPC matched
tissue microarray comprising of prostate tumour biopsy pairs at
diagnosis and after recurrence from the same individuals. SPRY2
levels were significantly lower in CRPC compared to matched HNPC
(Fig 1C and D). PTEN immunoreactivity in HN and CRPC paired
tumour samples was similar, with almost 50% of the HN and CRPC
matched cases showing no detectable PTEN expression (Fig EV1B).
Consistent with our previous reports on co-occurrence of SPRY2
and PTEN alterations in prostate cancer (Gao et al, 2012; Patel et al,
2013), SPRY2 and PTEN levels significantly correlated in CRPC
(Fig EV1C). Since SPRY2 expression was progressively lost from HN
state to CRPC, we hypothesised that SPRY2 deficiency may modu-
late tumour response to ADT.
To investigate if SPRY2 and PTEN deficiencies may mediate
CRPC, we used the genetically engineered mouse model of prostate
cancer, Nkx3.1 Ptenfl/+ Spry2fl/+ (hereafter referred as NPS) (Gao
et al, 2012). In the NPS model, the Nkx3.1 promoter-driven Cre
recombinase mediates heterozygous loss of Pten and Spry2 in the
AR-proficient luminal cells of the prostatic epithelium. The concomi-
tant heterozygous loss of Pten and Spry2 led to significant prostate
tumour burden after 50 weeks with nuclear AR, p-AKT and p-ERK1/
2 (Figs 1E and EV1D). Despite an initial favourable response to ADT
(achieved by castration), dual heterozygous loss of Pten and Spry2
led to CRPC, signified by comparable tumour burden and overall
survival in mock and ADT-treated mice (Figs 1F and G, and EV1D–
F). CRPC arising from the NPS model exhibited sustained nuclear
AR, p-AKT and p–ERK1/2 (Figs 1E and EV1G). We have previously
demonstrated that prostate-specific heterozygous loss of Spry2 does
not result in tumour formation, while the heterozygous loss of Pten
alone causes PIN (prostatic intraepithelial neoplasia) lesions (Gao
et al, 2012; Patel et al, 2013). In this study, the response to ADT
was found to be similar across wild-type, Spry2 heterozygous and
Pten heterozygous mice (Fig EV1H–J). We next investigated the
effects of SPRY2 on growth under hormone deprivation in LNCaP
cells, an AR-proficient prostate cancer cell line deficient for both
SPRY2 and PTEN (Fig EV1K). Consistent with our previous observa-
tions, SPRY2 overexpression significantly decreased the growth of
LNCaP cells in hormone-proficient conditions (FBS) (Figs 1H and
EV2A). Importantly, the SPRY2 overexpression-induced inhibition
of cell growth was significantly more profound under hormone-
deprived culture condition (Fig 1H).
To explore if SPRY2 could mediate resistance to ADT indepen-
dent of PTEN status, we investigated the levels of AR, PTEN and
SPRY2 in a panel of prostate cancer cell lines (Fig EV1K). AR- and
PTEN-proficient prostate cancer cell lines (CWR22Res, CWR22RV1
and VCaP) showed significantly enhanced expression of AR variants
including ARV7 (Figs EV1K and EV2B). Unlike CWR22RV1 cells, a
CRPC variant cell line (Sramkoski et al, 1999; Tepper et al, 2002),
the CWR22Res cells (Nagabhushan et al, 1996) retain their hormone
responsiveness and show a significant decrease in growth rate
under hormone-deprived conditions (Fig EV2C). It is worth noting
that CWR22RV1 expressed lower levels of SPRY2 than CWR22Res
cells. To further investigate the potential role of SPRY2 in mediating
CRPC, we stably knocked down SPRY2 in CWR22Res cells
(Fig EV2D). Compared to the non-silencing vector control cells
(Nsi), the stable knockdown (KD) of SPRY2 (CL3 and Pool) in
CWR22Res cells did not alter the growth rate in hormone-proficient
conditions (Fig 1I). Importantly, SPRY2-depleted CWR22Res cells
showed sustained growth rate even in hormone-deprived condition
(Fig 1I). In addition, we developed a murine prostate orthograft
model using CWR22Res cells. We surgically implanted CWR22Res
cells in one of the anterior prostate lobes in CD-1 nude mice. When
the prostate orthografts were either palpable or detectable by ultra-
sound imaging (typically at 30 days following implantation), the
mice were randomised to receive either ADT (by castration) or
mock treatment (sham surgery) (Fig EV2E and F). As expected,
following ADT, CWR22Res orthografts showed a significant reduc-
tion in growth rate compared to mock treatment (Fig EV2E and F).
We next studied CWR22Res SPRY2 KD generated orthografts to
investigate the role of SPRY2 in tumour response to ADT
(Fig EV2G). All mock-treated animals achieved maximum permitted
tumour burden around 73 days post-implantation irrespective of
SPRY2 status (Fig EV2H). While ADT-treated mice with Nsi ortho-
grafts survived longer than mock-treated mice, ADT-treated mice
with SPRY2-deficient orthografts showed signs of weight loss
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around 60 days (Fig EV2H and I). The ADT-treated mice with
SPRY2-deficient orthografts reached clinical endpoints between 60
and 70 days (Fig EV2H). Hence, we used a refined 60-days timed
experimental protocol for subsequent investigations. The ADT-
treated Nsi orthografts showed a significant reduction in orthograft
volume with increased ADT-induced tumour necrosis when
compared to mock-treated Nsi orthografts (Figs 1J and K, and EV2J
and K). Compared to Nsi orthografts, SPRY2-deficient orthografts
showed sustained growth under ADT conditions with minimal
ADT-induced tumour necrosis (Figs 1J and K, and EV2J). Since
CWR22Res cells express AR-V7 which may mediate CRPC progres-
sion, we next investigated the effects of SPRY2 KD on AR expression
(Watson et al, 2015). SPRY2 deficiency did not alter the expression
of AR (full length and V7; Fig EV2L).
The PTEN levels remained unaltered in all CWR22Res orthografts
(Fig EV2M). Mimicking the NPS model and LNCaP cells, by tran-
siently knocking down PTEN, we show that SPRY2 deficiency
provided a survival advantage under hormone-deprived conditions
independent of PTEN expression (Fig EV2N and O). Thus, SPRY2
deficiency may mediate resistance to ADT.
SPRY2 deficiency leads to androgen self-sufficient form of CRPC
To characterise SPRY2 deficiency-mediated ADT resistance, we
examined the status of AR in our orthografts. In response to ADT,
hormone-responsive Nsi orthografts showed decreased levels of AR
(full length and variants) and prostate-specific antigen (PSA), an AR
target gene expression (Figs 2A and B, and EV3A and B). In
contrast, SPRY2-deficient prostate orthografts maintained their AR
nuclear localisation, total levels of AR (full length and variants) and
PSA expression despite ADT (Figs 2A and B, and EV3A and B). We
further performed gene set enrichment analyses (GSEA) on microar-
ray-based transcriptomic profiles of CWR22Res Nsi control and
SPRY2 KD Pool cells. In GSEA, SPRY2-deficient cells showed signifi-
cant enrichment of steroid biosynthetic genes (Fig 2C). Together,
these observations suggested a potential role of SPRY2 deficiency in
mediating a type of CRPC with sustained AR activity.
Tumoral androgen biosynthesis may mediate the development of
CRPC with active AR pathway (Watson et al, 2015). To explore this,
we examined the androgen biosynthetic pathway in SPRY2-deficient
CRPC (Fig 2D). SPRY2-deficient orthografts in ADT-treated mice
maintained their intra-tumoral testosterone levels, despite castrated
levels of circulating testosterone (Fig 2E and F). Furthermore, only
under ADT conditions, SPRY2-deficient orthografts showed elevated
levels of tumoral cholesterol, an important precursor for androgen
biosynthesis (Fig 2G). Amongst the key androgen biosynthetic
enzymes [C17,20-lyase (CYP17A1), 3 beta-hydroxysteroid dehydro-
genase (HSD3B1) and 17 beta-hydroxysteroid dehydrogenase
(HSD17B1)], HSD3B1 expression was significantly increased in
SPRY2 KD CWR22Res cells (Fig EV3C and D). While CYP17A1
expression remained unaltered in orthografts, SPRY2-deficient pros-
tate orthografts showed a significant increase in HSD3B1 expression
in response to ADT (Figs 2A and H, and EV3E). The ADT-resistant
NPS tumours also showed elevated levels of HSD3B1 (Fig EV3F).
Furthermore, ectopic SPRY2 expression in LNCaP cells significantly
decreased expression of both CYP17A1 and HSD3B1 (Figs 2I and
EV3G). Similarly, compared to untreated VCaP (PTEN proficient
and SPRY2 deficient) prostate orthografts, tumoral HSD3B1 expres-
sion was significantly increased following ADT (Fig EV3H).
We next tested the sensitivity of SPRY2-deficient cells to the
CYP17A1 inhibitor abiraterone, which improves the treatment
response of prostate cancer patients when combined with standard-
of-care ADT (James et al, 2017). Abiraterone showed comparable
growth inhibition in control and SPRY2-expressing LNCaP cells in
both hormone-proficient and hormone-deficient conditions (Fig EV3I).
Interestingly, in hormone-deficient conditions, CWR22Res SPRY2
KD cells were less sensitive to abiraterone treatment compared to
Nsi controls (Fig EV3J). Since increased HSD3B1 expression can
mediate abiraterone resistance (Chang et al, 2013), we next
explored the importance of HSD3B1 in ADT-resistant SPRY2 defi-
cient cells. In CWR22Res cells, HSD3B1 knockout decreased the
growth rate of SPRY2-deficient cells in hormone-deprived conditions
with an associated decrease in the cellular testosterone levels
(Figs 2J and EV3K–M). Furthermore, HSD3B1 knockout enhanced
the sensitivity of ADT-resistant SPRY2-deficient cells to abiraterone
treatment (Fig 2J).
We have previously demonstrated that SPRY2 deficiency
promotes prostate carcinogenesis through aberrant HER2 signalling
◀ Figure 1. SPRY2 deficiency leads to CRPC.A Kaplan–Meier plot for the relapse-free survival of prostate cancer patients treated with androgen deprivation therapy (ADT). SPRY2-high patients, n = 14; SPRY2-
low patients, n = 13; log-rank (Mantel–Cox) test; P = 0.0189.
B Kaplan–Meier plot for overall (post-diagnosis) survival of ADT-treated prostate cancer patients. SPRY2-high patients, n = 12; SPRY2-low patients, n = 7; log-rank
(Mantel–Cox) test; P = 0.0306.
C Representative images for immunostaining for SPRY2 in HN (hormone-naïve) and CRPC (castration-resistant prostate cancer) matched clinical prostate cancer
sections. Scale bars = 100 lm.
D Immunostaining for SPRY2 in HN and CRPC matched clinical prostate cancer sections represented as IHC (immunohistochemistry) scores (n = 35 pairs; paired
two-tailed Student’s t-test; *P = 0.0009).
E Representative H&E and immunostained images of prostate sections from Nkx3.1 Ptenfl/+ Spry2fl/+ (NPS) mice. Scale bars = 100 lm.
F Prostate tumour burden 1 month post-ADT in NPS mice (n = 6 mice per group; unpaired two-tailed Student’s t-test; *P = 0.0009).
G Prostate tumour burden at clinical endpoint in NPS mice (n = 5 mice per group).
H, I Growth rate of LNCaP control and SPRY2-overexpressing cells (H); and CWR22Res Nsi (non-silencing) control and CL3 and Pool stable SPRY2 knockdown cell lines (I)
relative to T0 (Day 0) in hormone-proficient (FBS) medium and hormone-depleted (CSS) medium (n = 3; *P < 0.05; ANOVA Tukey’s test).
J CWR22Res prostate orthograft tumour volumes from 60-days timed experiment (n = 5 mice per group; *P < 0.05; ANOVA Tukey’s test).
K The effects of ADT on the CWR-22 prostate orthografts from 60-days timed experiment represented as % necrosis/tumour weight (n = 5 mice per group; *P < 0.05;
ANOVA Tukey’s test).
Data Information: In (D, F, G, J, K), each data point represents one independent observation. In (H, I), each data point is mean of three independent observations. In (D, F,
G–K), data are presented as mean  SD.
4 of 19 EMBO Molecular Medicine e8347 | 2018 ª 2018 The Authors
EMBO Molecular Medicine Targeting cholesterol transport in CRPC Rachana Patel et al
Published online: March 14, 2018 
A B C
D E
J
L M N
K
F G
H I
Figure 2.
ª 2018 The Authors EMBO Molecular Medicine e8347 | 2018 5 of 19
Rachana Patel et al Targeting cholesterol transport in CRPC EMBO Molecular Medicine
Published online: March 14, 2018 
(Gao et al, 2012). Compared to matched hormone-naı¨ve clinical PC,
HER2 immunoreactivity was significantly higher in CRPC (Fig 2K).
CWR22RV1 cells (CRPC variant of CWR22 cells) also showed
decreased levels of SPRY2 with increased levels of HSD3B1, HER2
and EGFR (Figs EV1K and EV3N). To test the role of HER2 in medi-
ating SPRY2 deficiency-induced treatment resistance, we stably
knocked down HER2 expression in Nsi and SPRY2 KD (Pool)
CWR22Res cells (Fig EV3O). HER2 KD significantly decreased
HSD3B1 expression and sensitised SPRY2-deficient orthografts to
ADT (Fig 2L–N), along with reduced AR expression (Fig 2N). Thus,
SPRY2 deficiency may facilitate treatment resistance by conferring
androgen self-sufficiency through HER-mediated induction of
HSD3B1.
SPRY2 deficiency-induced IL6 drives CRPC by elevating tumoral
HSD3B1 and cholesterol levels
We next sought to understand the underlying mechanisms of HER2-
driven treatment resistance in SPRY2-deficient CRPC. Since stress-
induced epithelial cytokines can facilitate androgen biosynthesis
(Chun et al, 2009), we profiled a panel of cytokines in the ortho-
grafts. Using a cytokine array, we identified IL6 as the most elevated
cytokine in the SPRY2-deficient orthografts (Fig EV4A). Consistent
with the data from cytokine profile, the SPRY2-deficient ADT-resis-
tant orthografts also showed elevated IL6 expression (Fig 3A).
HER2 KD diminished the IL6 expression in SPRY2-deficient ADT-
resistant orthografts (Fig 3B). Similarly, ectopic expression of SPRY2
in LNCaP cells decreased the IL6 expression (Fig EV4B).
We have previously shown that p38 MAP kinase is an important
mediator of HER2 activation following SPRY2 loss (Gao et al, 2012).
Consistent with this, we find elevated p-p38 levels in SPRY2-defi-
cient CWR22Res cells and p38 inhibitor treatment decreased IL6 and
HSD3B1 levels (Figs 3C and EV4C). In clinical prostate cancer
samples, HER2 levels significantly correlated with IL6 levels
(r = 0.2446; P = 0.0288; n = 80). In clinical CRPC, IL6 staining was
significantly increased compared to the matched hormone-naı¨ve
(HN) samples (Figs 3D and EV4D). Levels of SPRY2 and IL6 showed
a significant inverse correlation in ADT-treated prostate cancer
patients with evidence of biochemical relapse (r = 0.427;
P = 0.0261; n = 27; Fig EV4E). These observations may suggest an
enrichment of tumoral IL6 in a subset of CRPC samples with SPRY2
deficiency. Overall, androgen-independent CWR22RV1 and DU145
prostate cancer cells showed higher levels of IL6 expression
compared to hormone-responsive LNCaP and CWR22Res cells
(Fig EV4F).
Exogenous IL6 treatment increased HSD3B1 expression in
CWR22Res cells, and antibody-mediated IL6 neutralisation signifi-
cantly decreased both IL6 and HSD3B1 expression in SPRY2 defi-
cient cells (Fig EV4G and H). Thus, SPRY2 deficiency may mediate
CRPC by inducing HSD3B1 through HER2-IL6 cytokine axis. To test
the therapeutic impact of targeting IL6 signalling, we treated
CWR22Res orthograft-bearing mice with tocilizumab, an IL6 recep-
tor antagonist. Tocilizumab treatment significantly sensitised the
SPRY2-deficient castration-resistant orthografts to ADT (Fig 3E).
Tocilizumab treatment significantly decreased the expression of
HSD3B1, PSA and AR levels in SPRY2-deficient orthografts follow-
ing ADT (Figs 3F and G, and EV4I–K). Tocilizumab treatment also
suppressed IL6 expression, suggesting an IL6-driven feed-forward
autocrine loop within the orthografts (Fig 3H). We next studied the
effects of ADT and anti-IL6 combination therapy in NPS mice. The
addition of anti-IL6 treatment significantly sensitised NPS prostate
tumours to ADT, with significantly decreased tumoral AR (Figs 3I
and EV4L and M). In both orthograft and NPS models, IL6-neutra-
lising therapies did not alter the tumour burden in mock-treated
animals, indicating the importance of IL6 in tumour survival in the
context of ADT. Since in prostate cancer patients, treatment resis-
tance is frequently associated with enhanced risk of cancer metas-
tases, we characterised the incidence of visceral metastases in
◀ Figure 2. SPRY2 deficiency mediates androgen autonomous CRPC.A Representative immunoblot images for indicated proteins in lysates from indicated CWR22Res orthografts from 60-days timed experiment. HSC70 is used a loading
control.
B Relative quantitation of PSA mRNA in CWR22Res prostate orthografts from 60-days timed experiment (n = 5 mice per group; #P < 0.05 compared to Nsi mock;
*P < 0.05 compared to respective Nsi treatment; ANOVA Tukey’s test).
C GSEA analysis showing steroid biosynthetic process gene enrichment in CWR22Res SPRY2-deficient (Pool) cells compared to Nsi control cells.
D Schematic presentation of androgen biosynthesis pathway.
E, F Serum (E) and intra-tumoral (F) testosterone from mice bearing indicated orthografts from 60-days timed experiment measured using ELISA (n = 5 mice per group;
*P < 0.05; ANOVA Tukey’s test).
G Total cholesterol levels in indicated prostate orthografts from 60-days timed experiment (n = 3 mice per group; *P < 0.05; ANOVA Tukey’s test).
H Relative quantitation of human 3-b-hydroxysteroid dehydrogenase (HSD3B1) mRNA in CWR22Res prostate orthografts from 60-days timed experiment (n = 5 mice
per group; *P < 0.05; ANOVA Tukey’s test).
I Representative immunoblot images for indicated proteins in lysates from control and SPRY2-expressing LNCaP cells. HSC70 is used a loading control.
J Growth rate of HSD3B1 KO CWR22Res Nsi control and Pool stable SPRY2 KD cells relative to T0 in hormone-depleted (CSS) medium with indicated treatments
(n = 3; *P < 0.05 compared to CTRL VC at the indicated time; #P < 0.05 compared to all treatments at the indicated time; ANOVA Tukey’s test).
K Immunostaining for HER2 in HN and CRPC matched clinical prostate cancer sections represented as IHC scores (n = 35 pairs; *P < 0.0001; paired two-tailed
Student’s t-test).
L Relative quantitation of HSD3B1 mRNA in Nsi and Pool (SPRY2 KD) CWR22Res prostate cancer cells with stable expression of shSc (shScram) or shHER2 (n = 3;
*P < 0.05—shHER2 compared to respective shSc; unpaired two-tailed Student’s t-test).
M The effects of HER2 knockdown on CWR22Res orthografts represented as tumour volume (n = 5 mice per group; #P < 0.05 for Nsi orthografts; *P < 0.05 for Pool
orthografts; ANOVA Tukey’s test).
N Representative immunoblot images for indicated proteins in lysates from indicated CWR22Res orthografts from 60-days timed experiment. HSC70 is used a loading
control.
Data Information: In (B, E–H, K, M), each data point represents one independent observation. In (J), each data point is mean of three independent observations. In (B, E–
H, J–M), the data are presented as mean  SD.
Source data are available online for this figure.
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CWR22Res prostate orthograft and NPS models. We quantified the
incidence of proximal and distal visceral metastasis in each animal
based on histological examination and AR staining (Appendix Fig
S1A and B). The cumulative analyses of visceral metastases showed
increased metastatic incidence in mice bearing SPRY2-deficient
orthografts following ADT (Fig 3J). Surprisingly, tocilizumab treat-
ment increased the incidence of visceral metastases irrespective of
SPRY2 status, despite enhanced tumour response to ADT (Fig 3J).
Similarly, NPS mice treated with combined ADT and IL6-neutra-
lising antibody showed an increase in proximal and distant meta-
static incidence and burden (Fig 3K, Appendix Fig S1C–E). These
observations indicated that despite the importance of IL6 in driving
CRPC, systemic IL6 might play a role in governing metastatic
spread. These observations are consistent with a previously
reported role of IL6 in restraining the metastatic spread of Pten-
deficient prostate cancer (Pencik et al, 2015).
In addition to the effects on AR and HSD3B1, tocilizumab treat-
ment also normalised tumoral cholesterol levels in SPRY2-deficient
orthografts following ADT (Fig 3L). Hence, we hypothesised that
elevated intra-tumoral cholesterol levels may play a substantial role
in the emergence of treatment resistance and strategies to decrease
tumoral cholesterol may impact on CRPC.
SPRY2-deficient tumour-induced IL6 increases systemic
cholesterol levels
The increased intra-tumoral cholesterol in SPRY2-deficient ortho-
grafts following ADT is unlikely a result of enhanced tumoral
cholesterol synthesis since the expression of HMGCR (a rate-limiting
enzyme for cholesterol biosynthesis) was significantly lower in the
ADT-treated prostate orthografts (Fig 4A). Interestingly, the serum
cholesterol levels were significantly higher in castrated mice bearing
SPRY2-deficient orthografts (Fig 4B). The elevated serum choles-
terol levels may serve as a potential source of cholesterol in ADT-
resistant orthografts. Overall, all ADT-treated mice bearing prostate
orthografts, irrespective of SPRY2 status, showed elevated serum
triglyceride levels (Appendix Fig S2A).
Along with altered circulating cholesterol levels, in mice bearing
SPRY2-deficient tumours, serum IL6 levels were also significantly
raised following ADT (Fig 4C). Importantly, tocilizumab treatment
normalised the circulating levels of cholesterol and IL6 (Fig 4D and
E). Besides tumour-derived IL6, IL6 produced by the host adipose
tissue may also, at least in part, contribute to the observed
systemic increase in IL6 level (Appendix Fig S2B and C). Ectopic
IL6 stimulation of cultured adipocytes increased their IL6 expres-
sion, suggesting the possibility of an autocrine feed-forward loop in
the production of IL6 by adipocytes (Appendix Fig S2D). Our obser-
vations indicated a potential role of IL6 in elevating circulating
cholesterol, which may serve as a vital source of tumoral choles-
terol. We next investigated the association between CRPC and IL6
status in a clinical cohort. CRPC patients have elevated serum IL6
levels when compared to patients with untreated hormone-naı¨ve
(HN) prostate cancer (Fig 4F). Serum IL6 levels also significantly
correlated with serum PSA levels (Fig 4G). Importantly, CRPC
patients with high serum IL6 levels had poorer survival outcome
when compared to CRPC patients with low levels of serum IL6
(Fig 4H).
Since tumour-induced IL6 can induce dyslipidaemia (Flint et al,
2016), we next investigated the role of systemic IL6 on host lipid
metabolism in our models. Indicative of cancer cachexia, mice
harbouring SPRY2-deficient CRPC showed significant loss of
epididymal adipose tissue (Fig 4I, Appendix Fig S2E). Since tocili-
zumab treatment rescued this effect (Fig 4J), we further investigated
the potential underlying mechanism. Stimulation with exogenous
IL6 was adequate to mediate lipolysis in adipocytes as indicated by
decreased lipid staining (Appendix Fig S2F). Similarly, treatment
with IL6-neutralising antibody could reduce the observed lipolysis
(Appendix Fig S2G). Mechanistically, IL6 may mediate lipolysis
in adipocytes through PKA activation and loss of perilipin
(Appendix Fig S2H and I). Perilipin plays a central role in regulating
adipose lipolysis and associated rise in serum levels of free fatty
acids (Tansey et al, 2004; Zhai et al, 2010). Consistent with this,
mice bearing castration-resistant tumours showed significant loss of
perilipin in the epididymal adipose tissue along with elevated serum
levels of free fatty acids (FFAs), suggestive of host adipose lipolysis
(Fig 4K and L). Tocilizumab treatment diminished the observed
increase in systemic FFAs (Fig 4M). Importantly, in CRPC patients,
serum IL6 levels significantly correlated with serum levels of FFA
◀ Figure 3. SPRY2 deficiency-induced IL6 drives CRPC.A, B Relative quantitation of human IL6 mRNA in the indicated CWR22Res prostate orthografts (n = 5 for A and n = 3 for B mice per group; *P < 0.05 ANOVA Tukey’s
test).
C Relative quantitation of IL6 mRNA in Nsi and SPRY2 KD (Pool) CWR22Res cells treated for 16 h with the p38 inhibitor SB203580 (20 lM) (n = 3; *P < 0.05
compared to respective DMSO control; unpaired two-tailed Student’s t-test).
D Immunostaining for IL6 in HN and CRPC matched clinical prostate cancer sections represented as IHC scores (n = 35 pairs; *P = 0.05 paired two-tailed Student’s
t-test).
E The effects of tocilizumab treatment on CWR22Res orthografts represented as tumour volume (n = 5 mice per group; #P < 0.05 for Nsi orthografts; *P < 0.05 for
Pool orthografts; ANOVA Dunnett’s test).
F–H Relative quantitation of human (F) HSD3B1, (G) PSA and (H) IL6 mRNA in CWR22Res prostate orthografts (n = 5 mice per group; #P < 0.05 for Nsi orthografts;
*P < 0.05 for Pool orthografts; ANOVA Tukey’s test).
I Prostate tumour burden in mock- or ADT-treated NPS mice treated for 1 month with anti-IL6 or anti-IgG (control antibody) (n = 5 mice per group; *P < 0.05
unpaired two-tailed Student’s t-test).
J Cumulative visceral (proximal and distal as shown in Appendix Fig S1A) metastases incidence analysed from 10 sites per group (two sites: proximal and distal × 5
mice per group) in the mice with indicated CWR22Res orthografts. Chi-square test: P < 0.001.
K Representative AR immunostained images as indicated from NPS mice (n = 3). Scale bars = 10 lm.
L Total cholesterol levels in the indicated CWR22Res prostate orthografts (n = 3 mice per group; *P < 0.05 ANOVA Tukey’s test).
Data Information: In (A, B, D, E–I, L), each data point represents one independent observation. In (J), data presented as contingency graph. In (A–I, L), the data are
presented as mean  SD.
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(Fig 4N). Thus, systemic IL6 cytokine axis-induced host lipolysis
may increase both systemic and tumoral cholesterol levels.
SPRY2 deficiency-induced IL6 stimulates hepatic cholesterol
synthesis and tumoral SRB1 lipoprotein receptor expression
Mice with CRPC have elevated levels of circulating FFAs and choles-
terol. Circulating FFAs are typically cleared by the liver, predomi-
nantly by esterification to cholesterol. Liver also plays a central role
in cholesterol biosynthesis and transport. Hence, we explored the
hepatic function in mice bearing CPRC as a potential contributor to
elevated levels of circulating cholesterol. Indicating altered liver
function, mice with CRPC showed raised serum alanine transami-
nase activity and increased lipid droplets in the liver (Appendix Fig
S2J and K). Interestingly, ADT treatment itself, in non-tumour-
bearing mice, stimulated the expression of hepatic HMGCR, which
may suggest that elevated hepatic cholesterol biosynthesis may be
driven by systemic androgen deprivation (Appendix Fig S2L).
Hepatic HMGCR expression is further upregulated in mice bearing
CRPC and tocilizumab treatment normalised this effect (Fig 5A).
Consistent with the previous report (Flint et al, 2016), our observa-
tions support the idea that tumour-induced IL6 may modulate
hepatic function.
Overall, our work thus far indicated the potential contribution of
hepatic HMGCR function in elevating circulating cholesterol levels,
which may then serve as a source for tumoral cholesterol. To evalu-
ate the importance of cholesterol homeostasis in CRPC, we exploited
the well-documented effects of statins such as simvastatin (Del
Puppoo et al, 1995) to suppress systemic cholesterol biosynthesis.
Treatment with simvastatin significantly sensitised castration-resis-
tant orthografts to ADT (Fig 5B, Appendix Fig S2M and N).
Combined treatment of statin with ADT decreased the AR levels in
SPRY2-deficient orthografts (Appendix Fig S2O).
To investigate the uptake of cholesterol into the tumours, we
evaluated the tumoral levels of lipoprotein receptors that mediate
cholesterol transport and tissue distribution. SPRY2-deficient cells
showed enrichment of genes involved in lipoprotein binding
suggesting an active uptake of lipoproteins and their lipid content
(Fig 5C). While the expression of the low-density lipoprotein recep-
tor (LDLR) remained unaltered, CRPC orthografts showed enhanced
expression of scavenger receptor B1 (SRB1), a bidirectional high-
density lipoprotein (HDL) cholesterol receptor (Fig 5D and E).
Importantly, tocilizumab treatment significantly decreased SRB1
expression in CRPC orthografts (Fig 5F). Similarly, p38 inhibition
also decreased SRB1 expression in CWR22Res cell (Appendix Fig
S3A). We next investigated SRB1 levels in other CRPC models. VCaP
CRPC orthografts from castrated mice maintained the nuclear AR
levels and showed a dramatic increase in SRB1 staining (Fig 5G,
Appendix Fig S3B). Similarly, ADT-resistant NPS tumours also
showed increased p-p38 and SRB1 staining (Fig 5H, Appendix Fig
S3C).
SPRY2 deficiency mediates CRPC by increasing tumoral
cholesterol uptake through SRB1
We applied two complementary approaches (i) to genetically knock
out (KO) SRB1 expression (Fig EV5A and B) and (ii) to chemically
suppress SRB1 function with ITX5061 (a specific SRB1 antagonist;
Syder et al, 2011) in CWR22Res cells to investigate the functional
role of SRB1 in CRPC. Both SRB1 KO and ITX5061 treatment signifi-
cantly abrogated the growth advantage conferred by SPRY2 defi-
ciency under ADT conditions (Fig 6A). ITX5061 treatment did not
exhibit additional growth inhibition in SRB1 KO SPRY2-deficient
cells (Fig 6A). These data suggest that (i) SRB1 is required for
conferring the growth advantage to SPRY2-deficient cells under ADT
conditions, and (ii) ITX5061 mediated majority of its growth inhibi-
tory effects through SRB1 (Figs 6A and EV5C). Mechanistically,
SRB1 conferred growth advantage by enhancing HDL uptake under
ADT conditions (Fig 6B). SRB1 KO or ITX5061 treatment did not,
however, alter cellular LDL uptake (Fig EV5D). Similarly, LNCaP
and VCaP cells also uptake more HDL under ADT conditions
(Fig EV5E and F). Furthermore, ITX5061 treatment significantly
decreased the HDL uptake in LNCaP, VCaP and CWR22RV1 cells
(Fig EV5G–I). Since SRB1 is a bidirectional cholesterol transporter,
we also tested the effects of ITX5061 on cholesterol efflux. SPRY2-
deficient cells effluxed less cholesterol compared to the control cells
(Fig EV5J). ITX5061 treatment did not affect the overall cholesterol
efflux, suggesting the potential inhibitory role of ITX5061 in HDL
cholesterol uptake (Fig EV5J). ITX5061 decreased the growth of
LNCaP cells in hormone-deficient conditions (Fig EV5K). ITX5061
further inhibited the growth of CSS-sensitive SPRY2-overexpressing
LNCaP cells (Figs 1H and EV5K). ITX5061 treatment also decreased
the growth of CWR22RV1 CRPC cells (Fig EV5L).
To investigate the therapeutic importance of targeting SRB1, we
treated CWR22Res orthograft-bearing mice with ITX5061. Treatment
with ITX5061 significantly sensitised CRPC orthografts to ADT
◀ Figure 4. Tumour-induced IL6 increases systemic cholesterol levels.A Relative quantitation of human HMGCR mRNA in the indicated CWR22Res orthografts (n = 3 mice per group; *P < 0.05 ANOVA Tukey’s test).
B–E Total cholesterol (B, D) and IL6 (C, E) in sera from mice with CWR22Res prostate orthografts (n = 5 mice per group; *P < 0.05 ANOVA Tukey’s test).
F Serum levels of human IL6 in patients with hormone-naïve (n = 172) or castration-resistant (n = 129) form of prostate cancer (*P = 0.0002; unpaired two-tailed
t-test with Welch’s correction).
G Scatter plot showing correlation of serum levels of PSA and IL6 from prostate cancer patients.
H Kaplan–Meier plot for overall (post-diagnosis) survival of CRPC patients with no evidence of metastases (M0) segregated based on above median (high) and below
median (low) serum levels of IL6 (high IL6 = 9; low IL6 = 7; log-rank Mantel–Cox test; P = 0.004).
I, J The epididymal fat weights of mice bearing indicated CWR22Res orthografts (n = 5 mice per group; *P < 0.05 ANOVA Tukey’s test).
K Representative immunoblot image for perilipin in epididymal adipose tissue lysates from mice with CWR22Res prostate orthografts.
L, M Free fatty acids in sera from mice with indicated CWR22Res prostate orthografts (n = 5 mice per group; *P < 0.05 ANOVA Tukey’s test).
N Scatter plot showing correlation of serum levels of IL6 and free fatty acids (FFAs) from prostate cancer patients.
Data Information: In (A–G, I, J, L–N), each data point represents one independent observation. In (A–E; I, J, L, M), the data are presented as mean  SD.
Source data are available online for this figure.
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Figure 5. IL6 stimulates hepatic cholesterol synthesis and SRB1 expression in CRPC.
A Relative quantitation of murine Hmgcr mRNA in livers from mice with CWR22Res orthografts as indicated (n = 3 mice per group; *P < 0.05 ANOVA Tukey’s test).
B The effects of ADT and simvastatin on prostate orthografts represented as volume (n = 5 mice per group; #P < 0.05 for Nsi orthografts; *P < 0.05 for Pool
orthografts; ANOVA Tukey’s test).
C GSEA analyses showed enrichment of lipoprotein binding genes in CWR22Res SPRY2-deficient prostate cancer cells.
D–F Relative quantitation of human LDLR (D) and human SRB1 (E, F) mRNA in CWR22Res prostate orthografts (n = 5 mice per group for D & E and n = 3 mice per
group for F; *P < 0.05 ANOVA Tukey’s test).
G Representative images (n = 3) of AR and SRB1 immunoreactivity in VCaP prostate orthograft grown in intact (uncastrated) or castrated mice, signifying VCaP
hormone-naïve (HN) and VCaP castration resistance (CR) prostate cancer, respectively. Scale bar = 10 lm.
H Representative images (n = 3) of immunostained prostate sections from NPS mice as indicated. Scale bar = 10 lm.
Data Information: In (A, B, D–F), each data point represents one independent observation. In (A, B, D–F), the data are presented as mean  SD.
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(Figs 6C and EV5M and N). Mechanistically, ITX5061 (cholesterol
transport antagonist) and simvastatin (inhibitor of cholesterol
biosynthesis) treatments significantly decreased testosterone and its
precursor, androstenedione within the prostate orthografts under
ADT conditions (Fig 6D and E). ITX5061 treated orthografts showed
substantially lower levels of AR (Fig EV5O). In NPS mice, ITX5061
treatment significantly induced tumour regression, substantially
reducing nuclear AR level (Fig 6F and G, Appendix Fig S3D). Unlike
IL6-neutralising therapies, we did not observe any evidence of accel-
erated formation of visceral metastases in both orthograft and NPS
models following ITX5061 treatment (Fig 6H, Appendix Fig S3E).
The comparative growth inhibition study conferred higher growth
inhibitory potential to ITX5061 treatment compared to simvastatin
treatment in SPRY2-deficient CWR22Res and LNCaP cells under
hormone-deprived conditions (Appendix Fig S3F). Together, our
data indicate that ITX5061 may inhibit CRPC by inhibiting tumoral
cholesterol trafficking and simvastatin may mitigate CRPC by regu-
lating systemic cholesterol homeostasis.
To test the significance of SRB1 expression in clinical prostate
cancer, we characterised SRB1 expression by immunohisto-
chemistry (Fig 7A). Following ADT, the tumours with high levels of
SRB1 progressed to CRPC significantly faster (median time to
CRPC = 30 months) than those tumours with lower SRB1 expres-
sion (median time to CRPC = 48 months) (Fig 7B). Furthermore,
the SR-B1 expression at diagnosis also correlated significantly with
overall survival following treatment with ADT (Fig 7C).
Overall, we show that SPRY2 deficiency leads to an androgen
self-sufficient form of CRPC. Mechanistically, loss of the tumour
suppressor SPRY2 leads to activation of the HER2-IL6 cytokine
signalling axis, which enhances tumoral expression of androgen
biosynthetic enzyme HSD3B1 and lipoprotein receptor SRB1. At a
systemic level, IL6 induces host adipose lipolysis and stimulates
hepatic cholesterol biosynthesis leading to increased circulating
cholesterol. Thus, SPRY2 deficiency-driven p38-IL6 signalling axis
may support resistance to ADT by promoting self-sufficiency for
androgens within the tumour, at least in part, through increased
levels of intra-tumoral cholesterol required for androgen biosynthe-
sis (Fig 7D). Here, our key conclusion is that restoration of systemic
cholesterol homeostasis with the use of statins or the blockade of
SRB1-mediated tumoral cholesterol uptake can be potential strate-
gies to diminish treatment resistance in a subgroup of patients at
risk of developing CRPC.
Discussion
Therapeutic regimes designed to impair AR pathway activity remain
the first-line treatment for metastatic prostate cancer patients. Most
patients, even on the improved androgen-AR-targeted therapies,
eventually progress to castration-resistant prostate cancer (CRPC), a
lethal stage of the disease. Although certain CRPC forms are AR-
independent such as neuroendocrine (NEPC) and recently charac-
terised double-negative prostate cancer (DNPC—AR-negative
neuroendocrine negative), almost half of the CRPCs show reactiva-
tion of AR pathway (ARPC) (Watson et al, 2015; Bluemn et al,
2017). Defining the mediators of treatment resistance is critical in
designing effective therapeutic interventions. Experimental model-
ling of clinically relevant genomic lesions found in prostate
cancer can improve our understanding of treatment resistance
(Roychowdhury & Chinnaiyan, 2016). Loss of SPRY2 may represent
one such clinically relevant lesion, as patients with SPRY2-deficient
cancers show accelerated progression to CRPC with poor overall
survival. Here, using both in vitro and in vivo model systems includ-
ing human prostate orthograft and genetically modified (Gao et al,
2012) pre-clinical murine models, we uncovered a functional role of
SPRY2 deficiency in the progression of prostate cancer to CRPC state
through bidirectional tumour–host interactions.
We show that SPRY2 loss leads to an androgen self-sufficient
form of CRPC representing an ARPC (AR-active prostate cancer)
type of clinical CRPC (Watson et al, 2015). We have previously
shown how SPRY2 deficiency cooperates with loss of PTEN or PP2A
tumour suppressor activity to drive prostate cancer initiation (Patel
et al, 2013). We have also previously shown that SPRY2 deficiency
in a PTEN-dependent manner may amplify ligand-mediated activa-
tion of EGFR/HER2 RTK signalling axis (Gao et al, 2012). While
HER2 activation can drive the growth of SPRY2-deficient cells in a
PTEN-dependent manner, our current work further reveals that
SPRY2 deficiency can mediate progression to an AR-active CRPC
state irrespective of PTEN status. Mechanistically, the HER2-p38
signalling axis drives progression of SPRY2-deficient tumours to an
androgen autonomous castration-resistant state by inducing IL6
cytokine axis. The IL6 cytokine axis induces tumoral expression of
HSD3B1, a key androgen biosynthetic enzyme, and elevate tumoral
cholesterol uptake by enhancing the levels of scavenger receptor B1
(SRB1), an HDL receptor. The increase in IL6 levels in CRPC
tumours is closely associated with a systemic rise in circulating IL6.
▸Figure 6. SPRY2 deficiency-induced SRB1 mediates CRPC.A CWR22Res Nsi and SPRY2 (Pool) KD cells were subjected to SRB1 KO and/or treatment with ITX5061 as indicated. Cell numbers were normalised to T0 (Day 0) for
each cell line (n = 3; *P < 0.05 ANOVA Tukey’s test for all cell lines compared to Pool VC).
B HDL uptake in indicated cells grown in medium containing 10% FBS (FM) or 10% charcoal-stripped serum (ADT) treated with 15 lM ITX5061 (n = 3; *P < 0.05;
#P < 0.05 Nsi ADT CTRL compared to Pool ADT CTRL; ANOVA Tukey’s test).
C The effects of ITX5061 on CWR22Res prostate orthografts represented as tumour volume (n = 5 mice per group; #P < 0.05 for Nsi orthografts; *P < 0.05 for Pool
orthografts; ANOVA Tukey’s test).
D, E LC-MS-based detection of androstenedione (testosterone precursor) (#P < 0.05 for Nsi orthografts compared to Pool ADT vehicle; *P < 0.05 for Pool orthografts;
ANOVA Tukey’s test) (D) and testosterone (#P < 0.05 unpaired two-tailed Student’s t-test Nsi mock compared to Nsi ADT for respective treatments; *P < 0.05
ANOVA Tukey’s test compared to Pool ADT vehicle) (E) in CWR22Res prostate orthografts from mice treated as indicated (n = 3 mice per group).
F Prostate tumour weights from NPS mice treated with ITX5061 (n = 6; *P < 0.05 ANOVA Tukey’s test).
G Representative images (n = 5) of H&E and immunostained prostate sections from NPS mice treated with ITX5061. Scale bar = 10 lm.
H Incidence of cumulative visceral metastases was analysed from proximal and distal metastatic sites from mice bearing CWR22Res Nsi or Pool SPRY2 KD
orthografts, receiving treatments as indicated. Classification of proximal and distal metastases is shown in Appendix Fig S1A.
Data Information: In (C–F), each data point represents one independent observation. In (A), each data point represents mean  SD. In (H), data presented as contingency
graph. In (B–F), the data are presented as mean  SD.
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Furthermore, IL6-mediated systemic effects such as host lipolysis
and altered hepatic cholesterol homeostasis may aid disease
progression to CRPC through elevated levels of circulating choles-
terol. Thus, IL6 at both tumoral and systemic levels may drive
disease progression.
Besides full-length AR, both in vitro-cultured CWR22Res cells
and the in vivo orthograft model used in this study also express AR
variants that can promote castration resistance (Watson et al,
2015). Although AR variants may bypass the requirement of ligand
due to the absence of ligand binding domain, previous studies
suggest that AR variants including ARV7 may still respond to anti-
AR treatments targeting the ligand binding and continue to require
full-length AR to mitigate their function (Watson et al, 2010). In our
model system, treatments that sensitised orthograft response to ADT
also suppressed the expression of full-length and variant AR. Future
characterisation of the AR transcriptional activity under the condi-
tions that sensitised SPRY2-deficient models to ADT may provide
further understanding of AR reactivation in CRPC.
Our work highlights the importance of HER2 signalling in mediat-
ing progression of SPRY2-deficient cancer to CRPC. HER2 and the
downstream signalling cascades are potentially clinically actionable
targets and may play a functional role in driving treatment resistance
(Robinson et al, 2015; Shiota et al, 2015; Roychowdhury & Chin-
naiyan, 2016). In early phase I and II clinical trials, while HER/EGFR
inhibitors do not alter the disease progression in untreated hormone-
naı¨ve patients, a subset of CRPC patients treated with lapatinib, a
HER2/EGFR inhibitor, did show a decrease in disease progression
(Sridhar et al, 2010; Whang et al, 2013). Likewise, our work under-
scores the importance of HER2 in promoting tumour growth only
under ADT condition. Our work implicates a central role of IL6 in
HER2-mediated CRPC in SPRY2-deficient tumours. IL6 cytokine
signalling axis has been implicated in prostate cancer progression
and treatment resistance (Malinowska et al, 2009; Culig, 2014). IL6
being a pleiotropic cytokine may arise from multiple sources in
cancer patients. While reports indicate little IL6 production from
primary or metastatic clinical prostate cancer samples, the IL6 recep-
tor is present uniformly in a majority of prostate cancers (Siegall
et al, 1990; Culig, 2014; Yu et al, 2015). Importance of molecular
events such as SPRY2 loss or HER2 activation in tumoral IL6 produc-
tion in clinical prostate cancers needs further investigation. The
tumour microenvironment including infiltrating immune cells and
stromal tissue including prostate cancer-associated fibroblasts may
also substantially contribute to tumoral IL6 (Doldi et al, 2015). IL6
has been shown to promote both androgen-dependent and andro-
gen-independent forms of CPRP either by inducing tumoral androgen
biosynthetic cascade or by modulating ligand-independent functions
of AR (Kim et al, 2004; Chun et al, 2009). Our work suggests that in
SPRY2-deficient tumours IL6 may mediate AR-dependent CRPC
formation by facilitating tumoral androgen biosynthesis, at least in
part through enhanced androgen biosynthesis. Amongst the andro-
gen biosynthetic enzymes, while the expression of CYP17A1 may
not consistently alter based on SPRY2 status, the HSD3B1 levels were
elevated in all SPRY2-deficient CRPC models studied. In addition to
the expression of CYP17A1, HSD3B1 and HSD17B1, analyses of their
enzymatic activities in SPRY2-deficient cells may further aid in ascer-
taining the functional contributions of these androgen biosynthetic
enzymes in CRPC progression.
Accumulation of HSD3B1 protein is found to be sufficient to facil-
itate the emergence of CRPC by stimulating testosterone biosynthe-
sis from precursor sterols (Chang et al, 2013). Recently, the HSD3B1
status has been validated in prostate cancer patients as a robust
molecular determinant to predict unfavourable response to ADT
through testosterone synthesis (Hearn et al, 2016). Sharifi and
colleagues also implicate the potential role of HSD3B1 in developing
resistant to the CYP17A1 inhibitor abiraterone (Chang et al, 2013).
Abiraterone has significantly improved the prognosis and overall
survival in patients with advanced CRPC (Sartor & Pal, 2013). We
find that combining abiraterone with HSD3B1 depletion maximised
the growth inhibition of SPRY2-deficient CWR22Res cells in
hormone-depleted conditions. Of note, SPRY2 status did not alter
the response to abiraterone treatment in LNCaP cells. Both SPRY2-
proficient and SPRY2-deficient LNCaP cells exhibited similar abira-
terone-induced growth inhibition. Whether the differences observed
between CWR22Res and LNCaP models are a result of PTEN status
or presence of AR variants needs further investigation. Sharifi and
colleagues have recently shown that D4A, an active abiraterone
metabolite, can inhibit multiple androgen biosynthetic enzymes and
AR (Li et al, 2015). Whether D4A, a pan inhibitor of androgen
biosynthetic enzymes, sensitised CRPC with high HSD3B1 expres-
sion (e.g., SPRY2-deficient CRPC tumours) to ADT requires further
investigation.
In addition to steroid biosynthetic enzymes, cholesterol is an
important precursor for androgen biosynthesis, even in advanced
prostate cancer (Dillard et al, 2008). Majority of the cholesterol is
transported to various organs within low (LDL)- and high (HDL)-
density lipoproteins (Hu et al, 2010). Both LDLR (LDL receptor) and
SRB1 (HDL receptor) have been implicated in tumoral cholesterol
uptake and disease progression (Leon et al, 2010). While tumoral
LDLR levels did not change, we observed enhanced SRB1 expression
and HDL uptake in SPRY2-deficient ADT-treated orthografts.
Although SRB1 is a bidirectional cholesterol transporter, SPRY2-defi-
cient tumour cells take up more and efflux less cholesterol. This may
▸Figure 7. SRB1 in clinical prostate cancer.A Representative SRB1 immunostained images of prostate cancer samples. High SRB1 (n = 47) represents patients with SR-B1 IHC score above median, and low SRB1
(n = 43) represents patients with SR-B1 IHC score below median (scale bar = 10 lm).
B Kaplan–Meier plot for relapse-free survival of ADT-treated prostate cancer patients (SRB1-high patients = 11; SRB1-low patients = 11; log-rank Mantel–Cox test;
P = 0.006).
C Kaplan–Meier plot for overall (post-diagnosis) survival of patients treated with ADT (SRB1-high patients, n = 12; SRB1-low patients, n = 16; log-rank Mantel–Cox test;
P = 0.0354).
D SPRY2 deficiency facilitates progression of prostate cancer to CRPC through HER2-mediated induction of IL6, HSD3B1 and SRB1. IL6 cytokine axis, in a paracrine
manner, induces host adipose lipolysis and hepatic cholesterol synthesis, resulting in increased circulating cholesterol. ADT-resistant tumours take up cholesterol
through SRB1 for androgen biosynthesis. Normalising the systemic cholesterol homeostasis by statins and blocking SRB1-mediated cholesterol uptake by tumours
may serve as potential approaches to diminish treatment resistance in a subset of prostate cancers with the SPRY2 deficiency or HER2 activation.
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suggest cellular requirement to retain and use the cholesterol for
biomass and other biosynthetic needs including steroid biosynthesis.
Similar to our findings, SRB1 has a pro-survival function in C4-2
cells, which is a CRPC variant of LNCaP cells (Twiddy et al, 2012).
Furthermore, we find that cholesterol uptake by SRB1 seems to be
essential for the growth and survival of SPRY2-deficient cells under
ADT conditions. To date, the mechanisms that regulate SRB1 expres-
sion in CRPC have not been characterised. Here, we show that
besides regulating HSD3B1 expression, IL6 also regulates SRB1-
mediated cholesterol uptake in SPRY2-deficient CRPC cells. Consis-
tent with our clinical findings, a recent analysis of lipoprotein recep-
tors in clinical prostate cancer showed that SRB1 mRNA correlated
with HSD3B1 expression, and patients with high tumoral SRB1 levels
had shorter progression-free survival (Schorghofer et al, 2015).
The value of targeting the IL6 pathway in prostate cancer
including CRPC remains unclear (Culig, 2014). While IL6-targeting
therapies have not demonstrated clear effects on clinical outcomes
such as progression-free survival, there appeared to be a subgroup
of patients that demonstrated good PSA response as well as clinical
and radiologic evidence of stable disease (Dorff et al, 2010; Fizazi
et al, 2012). In our two complementary in vivo models, IL6-neutra-
lising therapies paradoxically increased the incidence of metastasis
despite sensitisation of primary tumours of ADT. Similar counterin-
tuitive increase in metastatic burden following anti-IL6 treatment
was recently reported in Pten-deficient prostate cancer model
(Pencik et al, 2015). The potential explanation for such unexpected
pro-metastasis effects following IL6-targeted treatment may be due
to the abrogation of IL6-STAT3 signalling-mediated regulation of
tumour suppressors such as TP53 (Pencik et al, 2015). Collectively,
our in vivo data on IL6-neutralising treatment suggest a complex
pattern of response, with improved local tumour response and
increased metastatic incidence. Despite evidence of increased metas-
tases in animals treated with IL6-neutralising therapies, we did not
find any correlation between serum IL6 levels and overall metastatic
burden in prostate cancer patients. This lack of association may be
attributed to a number of factors including the pleiotropic nature of
IL6, multiple IL6 sources and systemic inflammation that is
frequently associated with widespread metastases.
By understanding the disease progression at an organism level,
we find that IL6, in addition to mediating the tumoral treatment
resistance, also plays a central role in governing tumour–host inter-
actions to promote disease progression. As previously summarised
(Culig, 2014), we find that CRPC patients with high serum IL6 have
poor survival. Although systemic IL6 is closely associated with poor
patient survival, its functional role in facilitating CRPC by influenc-
ing host metabolism has not been fully understood. Tumour-induced
IL6 has been previously shown to mediate cachexia and treatment
response in other cancer models (Flint et al, 2016). Increase in circu-
lating IL6 can be a consequence of tumour-induced inflammation.
Here, we report that in addition to tumoral IL6 production, host visc-
eral adipose tissue may, at least in part, contribute to the rise in
systemic IL6. This elevated circulating IL6 may, in turn, induce host
adipose lipolysis (Rossi et al, 2015). In both pre-clinical treatment-
resistant mouse models and clinical CRPC, we found elevated circu-
lating levels of IL6 and free fatty acids (FFAs). IL6 mediates lipolysis
in adipocytes by inducing the loss of lipid droplet-associated protein
perilipin, which protects lipids within the droplet from intracellular
lipases. IL6-mediated inflammation can also alter hepatic cholesterol
homeostasis by inducing hepatic cholesterol biosynthesis (Zhao
et al, 2011). Consistent with this, systemic IL6 also stimulates
hepatic cholesterol biosynthesis in mice with CRPC leading to dyslip-
idaemia with elevated levels of circulating cholesterol. Thus, at a
systemic level, IL6 rewires host metabolism to raise circulating
cholesterol levels that may further facilitate prostate cancer progres-
sion towards a CRPC phenotype. Highlighting the importance of
cholesterol in the development of treatment resistance and overall
prognosis, retrospective clinical investigations found that men who
used statins after diagnosis of prostate cancer had a 24% decreased
risk of cancer-associated mortality (Yu et al, 2014). Similar to the
reported effectiveness of statins in inhibiting the progression of
LNCaP tumours to CRPC state (Wang et al, 2014), we show that
decreasing cholesterol bioavailability using statin treatment sensi-
tised SPRY2-deficient tumours to ADT. ITX5061 was previously
developed as an anti-viral agent (Syder et al, 2011) and was found to
be a clinically safe SRB1 specific antagonist. Our data support the
repurposing of ITX5061 in treating CRPC. ITX5061 treatment re-
sensitised prostate tumours to ADT by inhibiting SRB1-mediated
cholesterol uptake, thereby decreasing tumour androgen biosynthe-
sis. Further investigations are therefore warranted to robustly exam-
ine the effectiveness and safety of SRB1 antagonist such as ITX5061
to tackle treatment-resistant prostate cancer. Additional pre-clinical
models will be required to identify suitable patient groups and to
define the optimal treatment schedule in using ITX5061.
In our model, statins and ITX5061 act at two distinct nodes of
disease progression to sensitise tumours to ADT. While statins may
act by normalising hepatic cholesterol biosynthesis, ITX5061 as an
SRB1 antagonist may work by decreasing tumoral cholesterol
uptake. By studying CRPC at both tumour intrinsic (intra-tumoral)
and extrinsic (host) levels, we have identified two actionable nodes
that can sensitise prostate tumours to ADT. Thus, prostate patients
with SPRY2 loss or HER2 activation may progress to form androgen
autonomous AR-activated CRPC. This type of treatment-resistant
cancer may respond to treatments targeting systemic cholesterol
bioavailability (statins) and tumoral cholesterol transport (SRB1
antagonist, ITX5061).
Materials and Methods
Study approvals
All the animal experiments conducted for this study were carried
out with ethical approval from University of Glasgow under the
revised Animal (Scientific Procedures) Act 1986 and the EU Direc-
tive 2010/63/EU (PPL 30/3185). For clinical samples, ethical
approval was gained from the West of Scotland Research Ethics
Committed (05/S0704/94). The informed consent was obtained
from all subjects and that the experiments conformed to the princi-
ples set out in the WMA Declaration of Helsinki and the Department
of Health and Human Services Belmont Report.
Murine prostate cancer models
For prostate orthograft animal experiments, 14 × 106 CWR22Res
cells (Appendix Table S1) were surgically implanted in one of the
anterior prostate lobes of CD1-nude male mice (6–8 weeks old).
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CWR22Res prostate cancer cells with stable knockdown of SPRY2
were generated as described in Appendix information. After 30 days
when a palpable tumour was felt with 100% tumour incidence, the
mice were randomised into two groups: mock (sham surgical inci-
sion) and ADT (orchiectomy). A refined 60-days timed protocol was
used for all the treatment experiments. Nkx 3.1-Cre mice were
crossed to those harbouring Spry2fl/+ and Ptenfl/+, and mice were
genotyped by PCR by TransnetyxTM. After approximately 50 weeks,
the Nkx 3.1-Cre Ptenfl/+ Spry2fl/+ (NPS) developed palpable prostate
tumours (Gao et al, 2012). The mice with palpable prostate tumours
were randomised into two groups—mock (sham surgical incision)
and androgen deprivation therapy (ADT), which was achieved by
orchiectomy. NPS mice with mock or ADT treatment were sacrificed
1 month after treatment, and a subset of these mice was aged to clin-
ical end point. Drug treatments were initiated 3 days post-castration
(ADT): tocilizumab (100 lg in PBS given as I.P. injection 3 times a
week for 3 weeks), simvastatin (80 mg/kg/day in 30% PEG400 +
0.5% Tween 80 + 5% propylene glycol in water, gavaged daily for
1 month), and ITX5061 (25 mg/kg/day in 20% hydroxypropyl-beta-
cyclodextrin made in 20 mM citric acid, gavaged once daily for
1 month). Proximal metastases are defined as disease in lumber
lymph nodes and epididymal fat pads; distal metastasis is defined as
involvement of thoracic lymph nodes (diaphragmatic) and in the
lungs. Metastatic deposits were detected by H&E and confirmed by AR
immunostaining. Treatment response in prostate cancer orthografts
was calculated based on orthograft volume or using Leica image anal-
yser software to measure the total tumour area and central necrotic
area. The data were represented as % necrosis/tumour weight.
Steroid measurements
Serum and intra-tumoral testosterone levels were measured using
Testosterone EIA kit (Cayman Chemicals, 582701). For LC-MS-based
steroid detections (details provided in supplementary information),
the relative peak ratio was obtained by normalising the biological
sample peak area to the peak area obtained from the corresponding
fortified internal standard.
Clinical datasets for gene alterations and survival analyses
cBioPortal platform was used to query TCGA provisional prostate
cancer dataset. The data was extracted, and Kaplan–Meier survival
curves were plotted using GraphPad Prism.
Real-time PCR
10 lg of RNA was used for cDNA synthesis using high-capacity
cDNA reverse transcription kit (Applied Biosystems). Real-time PCR
was carried out using TaqMan Gene Expression Master Mix (Life
Technologies) in 7500 Fast Real-Time PCR System (Applied Biosys-
tems). CACS3 was used as the housekeeping gene, and the relative
quantities for each assay were obtained by normalising to one
biological control sample (as indicated in the figures).
Studies using clinical serum samples
Serum samples from 172 patients with HNPC and 129 patients with
CRPC were obtained from ProMPT study (ethics committee
approval: UK MREC number 01/4/61). Serum levels of PSA, FFA
and IL6 levels were measured in the same serum samples from indi-
vidual patients. The patients’ records were used to acquire the data
on PSA levels. The study criteria for IL6 and PSA correlation analy-
ses were to obtain the PSA level data on the same serum samples
(matched for sample collection date) from individual patients; 42
patients matched these criteria. Hence, IL6 and PSA correlation
analyses was performed in 42 samples. For FFA and IL6 correlation
analyses, a subset of 20 serum samples was requested from the
ProMPT study, randomly selecting 10 HNPC and 10 CRPC cases for
which IL6 levels were previously assayed. Out of these 20, 18
samples were analysed for FFA levels. Hence, the FFA and IL6
correlation data presented are for 18 samples.
Data analyses
Data plotting and statistical analysis were done using Prism Graph
Pad 7 (Appendix Table S2).
The paper explained
Problem
Prostate cancer is one of the most common cancers amongst men.
Treatment resistance and cancer metastases are leading causes of
cancer-associated mortalities in patients with prostate cancer. Pros-
tate cancer patients treated with androgen deprivation therapy (ADT),
a standard-of-care treatment for advanced disease, will eventually
progress to a lethal treatment-resistant state, referred to as castra-
tion-resistant prostate cancer (CRPC). Almost half of CRPC tumours
maintain their tumoral androgens and show evidence of androgen
receptor (AR) reactivation. Both tumour intrinsic molecular events and
host-tumour interactions can govern treatment response. Dual under-
standing of the tumoral molecular events and tumour–host cross talks
in mediating treatment resistance may help identify treatment strate-
gies that may improve the efficacy of current treatment modalities.
Results
Using an integrated approach to study treatment resistance in clinical
and murine pre-clinical models of prostate cancer, we show that loss
of tumour suppressor SPRY2, a negative regulator of receptor tyrosine
kinase signalling, leads to CRPC. Mechanistically, SPRY2 deficiency
mediates treatment resistance through HER2-driven IL6 cytokine axis.
SPRY2 deficiency-induced HER2-IL6 signalling mediates an androgen
autonomous form of CRPC through enhanced tumoral (i) HSD3B1
expression, a key androgen biosynthetic enzyme, and (ii) cholesterol
via the HDL receptor, SRB1. At a systemic level, the tumour-induced
IL6 cytokine axis elevated circulating cholesterol levels by inducing
host adipose lipolysis and hepatic cholesterol biosynthesis. Collectively,
our data illustrate how tumour-induced IL6 rewires host lipid metabo-
lism to promote treatment resistance by fuelling tumoral androgen
biosynthesis through enhanced cholesterol transport.
Impact
The tumoral cholesterol transport and systemic cholesterol homeosta-
sis play a significant role in facilitating treatment resistance. We
propose targeting cholesterol bioavailability using statins or tumoral
cholesterol uptake using ITX5061, a clinically safe SRB1 antagonist, as
two strategies to sensitise prostate tumours with SPRY2 deficiency or
HER2 activation to the standard-of-care androgen deprivation ther-
apy. Overall, we have identified SPRY2 deficiency as a driver of treat-
ment resistance, systemic IL6 as a circulating prognostic marker and
SRB1 as a clinically actionable target.
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Data availability
The Illumina microarray data are deposited in Geo Gene Expression
Omnibus: GEO Submission (GSE108456).
Expanded View for this article is available online.
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